{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:16:54Z","timestamp":1766024214794,"version":"3.48.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K08HL175130-01"],"award-info":[{"award-number":["1K08HL175130-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia with erythroid and megakaryocytic differentiation (AML-EMD) is a rare and aggressive presentation of AML characterized by overlapping morphologic, immunophenotypic, and genetic features of erythroid and megakaryocytic lineages. The classification, pathogenesis, and clinical behavior of this entity remain poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report a series of three patients in conjunction with a systematic review of reported cases in published literature with AML-EMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cytogenetic and molecular studies revealed frequent abnormalities including complex karyotypes,\n                      <jats:italic>TP53<\/jats:italic>\n                      mutations, and\n                      <jats:italic>JAK1\/2<\/jats:italic>\n                      mutations. Clinically, patients demonstrated a poor-risk profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Collective phenotypic and genetic features suggest that AML-EMD represents a high-risk subgroup of either\n                      <jats:italic>TP53<\/jats:italic>\n                      -mutated AML or AML with myelodysplasia-related genetics, likely reflecting leukemic transformation from multipotent progenitors retaining erythro-megakaryocytic potential. Despite shared biologic features, current classification systems for AML-EMD are diagnostically incongruent. Recognition of this entity will allow for consistent subclassification, prognostication, and future studies aimed at defining its molecular underpinnings and therapeutic vulnerabilities.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12308-025-00678-y","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:10:05Z","timestamp":1766023805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute myeloid leukemia with bipotential erythroid and megakaryocytic differentiation: a case series and literature review"],"prefix":"10.1007","volume":"18","author":[{"given":"Li-Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanelle J.","family":"De Lancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-9168","authenticated-orcid":false,"given":"Stephanie N.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"678_CR1","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, et al (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia 36(7):1703\u201319","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"11","key":"678_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"1","key":"678_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1309\/ajcprkyat6ezqhc7","volume":"144","author":"SA Wang","year":"2015","unstructured":"Wang SA, Hasserjian RP (2015) Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics: a guide to a number of perplexing entities. Am J Clin Pathol 144(1):44\u201360. https:\/\/doi.org\/10.1309\/ajcprkyat6ezqhc7","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"678_CR4","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41375-018-0145-6","volume":"32","author":"W Xiao","year":"2018","unstructured":"Xiao W, Rampal R, Zhang Y et al (2018) JAK\/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation. Leukemia 32(8):1842\u20131845. https:\/\/doi.org\/10.1038\/s41375-018-0145-6","journal-title":"Leukemia"},{"issue":"3","key":"678_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12185-014-1512-3","volume":"99","author":"W Jang","year":"2014","unstructured":"Jang W, Kim M, Lee JW, Chung NG (2014) Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma. Int J Hematol 99(3):213\u2013214. https:\/\/doi.org\/10.1007\/s12185-014-1512-3","journal-title":"Int J Hematol"},{"issue":"23","key":"678_CR6","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood.2021013227","volume":"138","author":"B Thakral","year":"2021","unstructured":"Thakral B, Lin P (2021) Acute myeloid leukemia with erythroid and megakaryocytic differentiation associated with Down syndrome. Blood 138(23):2446\u20132446. https:\/\/doi.org\/10.1182\/blood.2021013227","journal-title":"Blood"},{"issue":"5","key":"678_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1179\/acb.2007.047","volume":"62","author":"L Dani\u00ebls","year":"2007","unstructured":"Dani\u00ebls L, Guerti K, Vermeulen K et al (2007) Acute myeloid leukaemia of mixed megakaryocytic and erythroid origin: a case report and review of the literature. Acta Clin Belg 62(5):308\u2013314. https:\/\/doi.org\/10.1179\/acb.2007.047","journal-title":"Acta Clin Belg"},{"issue":"5","key":"678_CR8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/ijlh.13819","volume":"44","author":"SSW Chan","year":"2022","unstructured":"Chan SSW, Lee SY (2022) Acute megakaryocytic leukemia arising from megakaryocyte\/erythroid progenitor (MEP)-like cell. Int J Lab Hematol 44(5):808\u2013811. https:\/\/doi.org\/10.1111\/ijlh.13819","journal-title":"Int J Lab Hematol"},{"key":"678_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000411","author":"BJ Chernak","year":"2020","unstructured":"Chernak BJ, Sen F, Farnoud N et al (2020) Atypical presentation of erythroid\/megakaryocytic leukemic transformation of a myeloproliferative neoplasm associated with mutation and loss of TP53. HemaSphere. https:\/\/doi.org\/10.1097\/hs9.0000000000000411","journal-title":"HemaSphere"},{"issue":"3","key":"678_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ajh.26812","volume":"98","author":"B Falini","year":"2023","unstructured":"Falini B, Martelli MP (2023) Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. Am J Hematol 98(3):481\u2013492. https:\/\/doi.org\/10.1002\/ajh.26812","journal-title":"Am J Hematol"},{"issue":"3","key":"678_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/bloodadvances.2024014140","volume":"9","author":"SA Hart","year":"2025","unstructured":"Hart SA, Lee LA, Seegmiller AC, Mason EF (2025) Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications. Blood Adv 9(3):445\u2013454. https:\/\/doi.org\/10.1182\/bloodadvances.2024014140","journal-title":"Blood Adv"},{"issue":"5","key":"678_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1046\/j.1365-2141.1998.00904.x","volume":"102","author":"S Linari","year":"1998","unstructured":"Linari S, Vannucchi AM, Ciolli S et al (1998) Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias. Br J Haematol 102(5):1335\u20131337. https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00904.x","journal-title":"Br J Haematol"},{"issue":"3","key":"678_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2141.1995.tb05591.x","volume":"90","author":"E Ito","year":"1995","unstructured":"Ito E, Kasai M, Hayashi Y et al (1995) Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down\u2019s syndrome. Br J Haematol 90(3):607\u2013614. https:\/\/doi.org\/10.1111\/j.1365-2141.1995.tb05591.x","journal-title":"Br J Haematol"},{"issue":"25","key":"678_CR14","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1182\/blood.2021014465","volume":"139","author":"B Li","year":"2022","unstructured":"Li B, An W, Wang H et al (2022) BMP2\/SMAD pathway activation in JAK2\/p53-mutant megakaryocyte\/erythroid progenitors promotes leukemic transformation. Blood 139(25):3630\u20133646. https:\/\/doi.org\/10.1182\/blood.2021014465","journal-title":"Blood"},{"key":"678_CR15","doi-asserted-by":"publisher","unstructured":"Rampal R, Ahn J, Abdel-Wahab O et al (2014) Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci 111(50). https:\/\/doi.org\/10.1073\/pnas.1407792111","DOI":"10.1073\/pnas.1407792111"},{"issue":"4","key":"678_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1158\/2643-3230.BCD-24-0342","volume":"6","author":"AGX Zeng","year":"2025","unstructured":"Zeng AGX, Iacobucci I, Shah S et al (2025) Single-cell transcriptional atlas of human hematopoiesis reveals genetic and hierarchy-based determinants of aberrant AML differentiation. Blood Cancer Discov 6(4):307\u2013324. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0342","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"678_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O et al (2019) The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov 9(7):910\u2013925. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0125","journal-title":"Cancer Discov"},{"issue":"3","key":"678_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","volume":"99","author":"YW Wang","year":"2020","unstructured":"Wang YW, Tsai CH, Lin CC et al (2020) Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol 99(3):501\u2013511. https:\/\/doi.org\/10.1007\/s00277-020-03911-z","journal-title":"Ann Hematol"},{"issue":"13","key":"678_CR19","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/blood.2021011094","volume":"141","author":"H Kuusanm\u00e4ki","year":"2023","unstructured":"Kuusanm\u00e4ki H, Dufva O, V\u00e4h\u00e4-Koskela M et al (2023) Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood 141(13):1610\u20131625. https:\/\/doi.org\/10.1182\/blood.2021011094","journal-title":"Blood"},{"issue":"9","key":"678_CR20","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41375-025-02711-6","volume":"39","author":"A Bazinet","year":"2025","unstructured":"Bazinet A, Loghavi S, Wei Y et al (2025) Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256\u20132265. https:\/\/doi.org\/10.1038\/s41375-025-02711-6","journal-title":"Leukemia"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00678-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-025-00678-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00678-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:10:12Z","timestamp":1766023812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-025-00678-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["678"],"URL":"https:\/\/doi.org\/10.1007\/s12308-025-00678-y","relation":{},"ISSN":["1868-9256","1865-5785"],"issn-type":[{"value":"1868-9256","type":"print"},{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Indiana University Institutional Review Board (IRB). For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"For this type of study, consent for publication is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was approved as non-human subjects research by the Indiana University IRB and therefore consent was not required.\u00a0Loss of follow up of patients additionally prohibited pursuit of formal consent to publish. All published data are anonymized and there\u00a0are no images that allow identification of patients. Therefore, we hope the editorial board can make an exception to the requirement\u00a0for formal consent. If documentation from the IU IRB is required, we can certainly provide this.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"62"}}